The FDA granted approval to Altuviiio as a first-in-class, high-sustained factor VIII replacement therapy for hemophilia A patients on February 22, 2023.

Nkarta Reveals Start of Clinical Trial Led by Investigators for NKX019 in Treating Systemic Lupus Erythematosus.

The FDA granted accelerated approval to Sparsentan for its ability to reduce proteinuria (excess protein in the urine) in adults with primary immunoglobulin A nephropathy.

Inimmune reports initial cancer patient treated in a phase 1 trial with its new TLR7/8 agonist immunotherapy, INI-4001.

Pirtobrutinib, marketed under the brand name Jaypirca, is FDA approved. The FDA granted accelerated approval to Pirtobrutinib on January 27, 2023.

Transposon Reports Conclusive Data from Phase 2 Trial of TPN-101 Targeting C9orf72-Linked ALS and/or Frontotemporal Dementia.

Elacestrant was approved by the FDA on January 27, 2023, for the treatment of advanced or metastatic breast cancer in postmenopausal women and adult men.

Sage Therapeutics and Biogen Reveal Key Findings from Phase 2 KINETIC 2 Trial of SAGE-324 (BIIB124) for Essential Tremor Treatment.

The FDA approved Bexagliflozin under the brand name Brenzavvy on January 20, 2023.

Pfizer Inc. revealed encouraging topline outcomes from the Phase 3 AFFINE trial, which assesses giroctocogene fitelparvovec.

The FDA approved the combination of albuterol and budesonide under the brand name Airsupra on January 10, 2023.

This trial aims to assess the efficacy and safety of petosemtamab, a Biclonics targeting EGFR and LGR5.